{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:42:52Z","timestamp":1789994572213,"version":"4.0.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age\u2009=\u200958\u2009years; men\u2009=\u200968%; diffuse large B-cell lymphoma\u2009=\u200987%; inpatient CAR-T therapy\u2009=\u200985%). Our peri\u2013CAR-T period of interest was from 41 days before to 154\u2009days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608\u200a100 (interquartile range, IQR\u2009=\u2009$534\u200a100-$732\u200a800); 8.5% of patients had total costs exceeding $1\u00a0million. The median cost of CAR-T therapy products was $402\u200a500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median\u2009=\u2009$521\u200a500), with median costs below $25\u200a000 in all other 28-day intervals. Costs of CAR-T therapy use were substantial, largely driven by product acquisition. Future studies should examine the relationship between costs, access, and financial outcomes.<\/jats:p>","DOI":"10.1093\/jncics\/pkae059","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:52:12Z","timestamp":1723053132000},"source":"Crossref","is-referenced-by-count":25,"title":["Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"},{"name":"Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University , New Haven, CT, USA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington\/Fred Hutchinson Cancer Center , Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal C","family":"Potnis","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B","family":"Long","sequence":"additional","affiliation":[{"name":"Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Seropian","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P","family":"Gross","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"},{"name":"Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F","family":"Huntington","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT, USA"},{"name":"Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"10254","key":"2024082222553564200_pkae059-B1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2024082222553564200_pkae059-B2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10343","key":"2024082222553564200_pkae059-B3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"2024082222553564200_pkae059-B4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"2024082222553564200_pkae059-B5","first-page":"2307","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024082222553564200_pkae059-B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2024082222553564200_pkae059-B7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024082222553564200_pkae059-B8","author":"Nastoupil"},{"issue":"7","key":"2024082222553564200_pkae059-B9","doi-asserted-by":"crossref","first-page":"404.e401","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024082222553564200_pkae059-B10","doi-asserted-by":"crossref","first-page":"e19500","DOI":"10.1200\/JCO.2021.39.15_suppl.e19500","article-title":"Chimeric antigen receptor T-cell therapy real-world assessment of total cost of care and clinical events for the treatment of relapsed or refractory lymphoma","volume":"39(suppl 15)","author":"Sahli","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024082222553564200_pkae059-B11","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"issue":"4","key":"2024082222553564200_pkae059-B12","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024082222553564200_pkae059-B13","doi-asserted-by":"crossref","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Mark Access Health Policy"},{"issue":"11","key":"2024082222553564200_pkae059-B14","doi-asserted-by":"crossref","first-page":"e2135123","DOI":"10.1001\/jamanetworkopen.2021.35123","article-title":"Characteristics of cost-effectiveness studies for oncology drugs approved in the United States From 2015-2020","volume":"4","author":"Haslam","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024082222553564200_pkae059-B15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1377\/hlthaff.2021.01742","article-title":"Many Medicare beneficiaries do not fill high-price specialty drug prescriptions","volume":"41","author":"Dusetzina","year":"2022","journal-title":"Health Aff (Millwood)"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkae059\/58776242\/pkae059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/4\/pkae059\/58890619\/pkae059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/4\/pkae059\/58890619\/pkae059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:47:14Z","timestamp":1724370434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkae059\/7730013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkae059","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,1]]},"article-number":"pkae059"}}